A novel artificial intelligence test developed to identify men who will benefit from abiraterone significantly reduces prostate cancer mortality, potentially halving death risk. This advancement showcases AI’s potential in personalized medicine, with implications for healthcare systems and patient outcomes across various countries, prioritizing targeted treatment strategies.
🔬 AI Predicts Prostate Cancer Drug Candidates
